OTCPK:PCHM

Stock Analysis Report

Executive Summary

PharmChem, Inc. provides PharmChek Sweat Patch that is used to detect drugs of abuse.

Snowflake

Fundamentals

Adequate balance sheet with weak fundamentals.

Risks

  • PharmChem has significant price volatility in the past 3 months.
  • PharmChem's last earnings update was 5604 days ago.
  • PharmChem is not covered by any analysts.

Share Price & News

How has PharmChem's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

3.3%

OTCPK:PCHM

1.5%

US Medical Equipment

0.8%

US Market


1 Year Return

82.4%

OTCPK:PCHM

9.7%

US Medical Equipment

1.9%

US Market

PCHM outperformed the Medical Equipment industry which returned 9.6% over the past year.

PCHM outperformed the Market in United States of America which returned 2.1% over the past year.


Share holder returns

PCHMIndustryMarket
7 Day3.3%1.5%0.8%
30 Day14.8%0.7%3.4%
90 Day106.7%2.4%2.1%
1 Year113.9%82.4%10.6%9.7%4.2%1.9%
3 Year1300.1%933.3%70.2%65.0%46.7%37.2%
5 Year2370.8%1723.5%136.0%109.1%62.3%44.5%

Price Volatility Vs. Market

How volatile is PharmChem's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is PharmChem undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether PharmChem is trading at an attractive price based on the cash flow it is expected to produce in the future. But as PharmChem has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Examine PharmChem's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through PharmChem regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is PharmChem expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.1%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as PharmChem has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has PharmChem performed over the past 5 years?

0.2%

Historical Healthcare annual earnings growth


In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, PharmChem has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Next Steps

Financial Health

How is PharmChem's financial position?


In this section we usually analyse PharmChem's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. PharmChem has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of PCHM’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when PharmChem's financial data was last updated here.
  • Explore more healthy companies in the Healthcare industry.

Dividend

What is PharmChem's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate PharmChem's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate PharmChem's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as PharmChem has not reported any payouts.

Unable to verify if PharmChem's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as PharmChem has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of PharmChem's salary, the management and board of directors tenure and is there insider trading?

22.6yrs

Average board tenure


CEO

Joe Halligan (74yo)

23.8yrs

Tenure

US$415,781

Compensation

Mr. Joseph W. Halligan also known as Joe has been the President and Chief Executive Officer of PharmChem, Inc. since November 1995. From 1988 to 1995, Mr. Halligan was President and Chief Executive Officer ...


Board Age and Tenure

22.6yrs

Average Tenure

77yo

Average Age

The average tenure for the PharmChem board of directors is over 10 years, this suggests they are a seasoned and experienced board.


Insider Trading

No 3 month open market individual insider trading information.


Management Team

  • Joe Halligan (74yo)

    Chief Executive Officer

    • Tenure: 23.8yrs
    • Compensation: US$415.78k
  • David Lattanzio (76yo)

    Chief Financial Officer

    • Tenure: 23.4yrs
    • Compensation: US$252.91k

Board Members

  • Dick Irwin (80yo)

    Chairman of the Board

    • Tenure: 23.8yrs
  • Joe Halligan (74yo)

    Chief Executive Officer

    • Tenure: 23.8yrs
    • Compensation: US$415.78k
  • Donald Stroben (88yo)

    Director

    • Tenure: 21.3yrs
  • Stephen Schorr (73yo)

    Director

    • Tenure: 18.3yrs

Company Information

PharmChem, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: PharmChem, Inc.
  • Ticker: PCHM
  • Exchange: OTCPK
  • Founded:
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$9.072m
  • Shares outstanding: 5.85m
  • Website: https://www.pharmchek.com

Location

  • PharmChem, Inc.
  • 2411 East Loop 820 North
  • Fort Worth
  • Texas
  • 76118
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PCHMOTCPK (Pink Sheets LLC)YesCommon StockUSUSDAug 1991

Biography

PharmChem, Inc. provides PharmChek Sweat Patch that is used to detect drugs of abuse. Its PharmChek Sweat Patch uses sweat as the source and offers alternative to urine testing for cocaine, opiates, amphet ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/17 23:49
End of Day Share Price2019/09/17 00:00
Earnings2004/03/31
Annual Earnings2003/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.